Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 0.73 |
| ▸ | RAB9A | P51151 | 5/20 | 0.72 |
| ▸ | NPC1 | O15118 | 4/20 | 0.72 |
| ▸ | MAPT | P10636 | 4/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | HTT | P42858 | 3/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.67 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.65 |
| ▸ | PARP1 | P09874 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10699534 | 0.87 | ABL1 (0.73) | ABL1RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL10813540 | 0.87 | MAPT (0.88) | RAB9ANPC1MAPTALDH1A1MEN1 | |
| SCHEMBL10921715 | 0.87 | MAPT (0.72) | RAB9ANPC1MAPTALDH1A1MEN1 | |
| SCHEMBL3823589 | 0.87 | MAPT (0.72) | RAB9ANPC1MAPTALDH1A1MEN1 | |
| SCHEMBL28200307 | 0.86 | ABL1 (0.76) | ABL1RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL1822161 | 0.86 | KMT2A (0.73) | RAB9ANPC1MAPTALDH1A1MEN1 | |
| SCHEMBL24074023 | 0.85 | MEN1 (0.67) | ABL1RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL16607163 | 0.85 | ALDH1A1 (0.79) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL30142924 | 0.85 | MEN1 (0.67) | ABL1RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL10697632 | 0.85 | ALDH1A1 (0.76) | ABL1RAB9ANPC1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100506807-C | Amide derivatives as GK activators | NOVO NORDISK AS (DK) | 2009-07-01 | — | — | CN | claimed |
| CN-101434585-A | Amide derivatives as GK activators | NOVO NORDISK AS (DK) | 2009-05-20 | — | — | CN | claimed |
| CN-1658871-A | Amide derivatives as GK activators | NOVO NORDISK AS (DK) | 2005-08-24 | — | — | CN | claimed |
| US-6903090-B2 | Such as 10-(2-ethoxyphenyl)-1,2,3,4,5,6-hexahydroazepino(4,5-b)indole; for treatment of anxiety, depression, schizophrenia, epilepsy, migraine, Alzheimers disease, sleep disorders, obesity, stress related diseases, and/or drug withdrawal | PFIZER (US) | 2005-06-07 | — | — | US | claimed |
| US-6828314-B2 | Modulation of the activity of serotonin receptors (5-HT) to treat diseases such as anxiety, depression or obesity | PFIZER | 2004-12-07 | — | — | US | claimed |
| US-20030225058-A1 | Substituted azepino[4,5b]indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2003-12-04 | — | — | US | claimed |
| US-20030220321-A1 | Substituted azepino[4,5b]indole derivatives | PHARMACIA & UPJOHN COMPANY | 2003-11-27 | — | — | US | claimed |
| US-6586421-B2 | For therapy of central nervous system, including diseases, disorders, and conditions related to, such as anxiety, depression, hypertension, migraine, obesity, compulsive disorders, schizophrenia, autism, neurodegenerative disorders | PHARMACIA & UPJOHN COMPANY | 2003-07-01 | — | — | US | claimed |
| EP-1319005-A2 | SUBSTITUTED AZEPINO[4,5-B]INDOLINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-18 | — | — | EP | claimed |
| EP-1319004-A2 | SUBSTITUTED AZEPINO[4,5-B]INDOLE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-18 | — | — | EP | claimed |
| US-20020107278-A1 | Substituted azepino[4,5b]indole derivatives | PHARMACIA & UPJOHN COMPANY | 2002-08-08 | — | — | US | claimed |
| US-20020077318-A1 | Substituted azepino[4,5b] indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2002-06-20 | — | — | US | claimed |
| WO-2002024701-A2 | SUBSTITUTED AZEPINO[4,5B)INDOLE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | claimed |
| WO-2002024700-A2 | SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | claimed |
| US-20230138480-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-04 | — | — | US | disclosed |
| EP-3416960-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2021-12-01 | — | — | EP | disclosed |
| EP-3416960-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2021-12-01 | — | — | EP | disclosed |
| US-20020077318-A1 | Substituted azepino[4,5b] indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2002-06-20 | — | — | US | disclosed |
| WO-2002024701-A2 | SUBSTITUTED AZEPINO[4,5B)INDOLE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002024700-A2 | SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107278-A1 | Substituted azepino[4,5b]indole derivatives | HTR5A, HTR1A, HTR1E | ABL1 591/4885RAB9A 698/4885NPC1 1345/4885 |
| US-20230138480-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | ABL1 714/4885RAB9A 572/4885NPC1 138/4885 |
| US-20030225058-A1 | Substituted azepino[4,5b]indoline derivatives | HTR5A, HTR1A, HTR4 | ABL1 554/4885RAB9A 751/4885NPC1 1176/4885 |
| US-20030220321-A1 | Substituted azepino[4,5b]indole derivatives | HTR5A, HTR1A, HTR1E | ABL1 591/4885RAB9A 698/4885NPC1 1345/4885 |
| US-20020077318-A1 | Substituted azepino[4,5b] indoline derivatives | HTR5A, HTR1A, HTR4 | ABL1 554/4885RAB9A 751/4885NPC1 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.